Gemcitabine plus oxaliplatin for treatment of advanced primary liver cancer

Objective:To analyze the efficacy and safety of oxaliplatin combined with gemcitabine(GEMOX) for treatment of patients with advanced primary liver cancer(PLC).Methods:Thirty patients with advanced PLC received the systemic chemotherapy of GEMOX regimen.The efficacy and toxicity were evaluated every 2 cycles by the criteria of Response Evaluation Criteria in Solid Tumors,version 1.1 and the National cancer institute-common terminology criteria adverse events,version 4.0.Results:All the 30 patients were evaluable for short-term efficacy.Partial response was observed in 2 cases,stability in 22 cases and progression in 6 cases.The objective response rate was 6.7% and the disease control rate was 80.0%.The median time to progression and the overall survival time were 3.9 and 9.4 months,respectively.Clinical symptoms and Karnofsky scores were improved in 25 cases.The main adverse effects were hematologic toxicity,alopecia,mild to moderate gastrointestinal reaction and mild periphery neurotoxicity,which returned to normal after treatment.Conclusions:GEMOX regimen is effective for treatment of advanced PLC with tolerable adverse effects.